SEC Tracker
Get the app

Arbutus Biopharma ABUS

Arbutus Biopharma announces Q3 2026 results and updates

Arbutus Biopharma (ABUS) filed an 8-K with the SEC on Nov 10, 2026, 7:33 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities of $337.5M as of September 30, 2026
  2. Returned $230M to shareholders via tender offer in October 2026
  3. FDA lifted clinical hold on AB-101 IND application
  4. Expanded LNP patent infringement lawsuits in Japan and Canada

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Arbutus Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.